Anticancer drug treatments lead to the activation of the PERK/eukaryotic initiation factor 2α (eIF2α)/CHOP signaling pathway in response to ER stress; when signaling does not lead to cell death, however, increased ABCC1/MRP expression has been observed in ER stress-resistant breast cancer cells [162]. The gene discussed is DDIT3; the disease is breast carcinoma.